DDInter813 DDInter1676
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Gemifloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Gemifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Gemifloxacin {u} (Compound) causes {v} (Side Effect) Tendon rupture
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Triamcinolone
Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Gemifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Gemifloxacin (Compound) causes Tendon rupture (Side Effect)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Gemifloxacin may lead to a major life threatening interaction when taken with Nilotinib
Gemifloxacin may lead to a major life threatening interaction when taken with Triamcinolone